|Bid||168.22 x 1400|
|Ask||178.80 x 1100|
|Day's range||170.79 - 175.00|
|52-week range||133.20 - 202.60|
|Beta (5Y monthly)||0.82|
|PE ratio (TTM)||53.49|
|Earnings date||28 Oct 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||189.00|
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seagen's (NASDAQ:SGEN) stock is up by a considerable 18% over the past three months. Since the market usually pay for a...
BOTHELL, Wash. & TOKYO, October 12, 2021--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that patient enrollment was completed in Cohort K of the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869). The cohort is evaluating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or me